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Background: Acne vulgaris is a chronic disease with several pathogenic factors. Multiple 
medications are typically used that can lead to nonadherence and treatment failure. Combination 
medications target multiple pathways of acne formation and may offer therapeutic benefit.
Purpose: To explore the efficacy and tolerability of combination retinoid plus antimicrobial 
treatments in acne vulgaris.
Methods: A PubMed and Google search was conducted for combination therapies of 
clindamycin and tretinoin, with secondary analysis of related citations and references. Similar 
searches were completed for the combination medications of benzoyl peroxide plus clindamycin 
or erythromycin, and for the combination therapy of adapalene and benzoyl peroxide.
Results: Combination clindamycin phosphate and tretinoin gel was found to be more efficacious 
than monotherapy of either drug or its vehicle for acne, including inflammatory acne, and has a 
greater onset of action than either drug alone. Clindamycin phosphate and tretinoin gel was 
well-tolerated, and adherence to its use exceeded that of using both medications in separate 
formulations. Benzoyl peroxide-containing combination medications with clindamycin or 
erythromycin were both more effective in the treatment of acne than either drug alone. Both 
medications were well-tolerated, with dry skin being the most common adverse effect.
Conclusions: Combination medications have superior efficacy and adherence, and have a 
similar tolerability profile compared with monotherapy of its components. Several studies have 
found antibiotic-containing combination products with a retinoid effective for acne. The use of 
antibiotic-containing combination medications for acne can lead to bacterial resistance. Due 
to this potential for bacterial resistance, benzoyl peroxide treatments are also recommended in 
combination with a retinoid.
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Introduction
Acne vulgaris is a chronic inflammatory dermatosis that consists of open and closed 
comedones, papules, pustules, and nodules.1 It represents the most common skin disease 
in the population, affecting 40–50 million individuals of all races and ethnicities in 
the US.2–4 Acne can affect neonates, teenagers, and adults, with its prevalence peaking 
during the teenage years at 85% and remaining at 8% through adulthood.2 Furthermore, 
the patient age for visits to a physician for acne is decreasing with the decreasing age 
of puberty onset.5 Although a common disease, it can affect an individual emotionally 
and functionally in a manner comparable to someone with psoriasis, a condition 
known to cause significant morbidity.6,7 This significant psychosocial impact results 
in patients desiring treatment, and it has been shown that medical treatment has led 
to improvement of these factors.8,9Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Pathogenesis of acne
The classically described pathogenesis of acne is multi-
factorial and originates at the pilosebaceous unit (PSU), 
which consists of large, multilobulated sebaceous glands, an 
epithelial-lined follicular canal, and a hair (Figures 1 and 2).3 
In normal skin, sebum carries shed follicular   epithelial 
cells to the skin’s surface unobstructed. However, in acne 
vulgaris, there is occlusion of the PSU by excess sebum 
production and/or increased cell turnover of the follicular 
canal. This results in bacterial overgrowth of, primarily, 
Propionibacterium acnes, an ensuing immune reaction, and 
inflammation.3 The combination of excess sebum production, 
dysfunctional epithelium development or desquamation, 
bacterial overgrowth, and immune reaction collectively lead 
to the development of acne vulgaris.
Microcomedones are the precursors to acne and are not 
visible on clinical examination. They can progress to nonin-
flammatory lesions, or open and closed comedones, which 
both consist of sebum and shed keratinocytes (Figure 3).3 
Both types of comedones can develop into inflammatory 
  papules, nodules, or pseudocysts. Nodules and pseudocysts 
are present in severe forms of acne and may result in scar-
ring if left untreated.
New developments have expanded upon the   classical 
pathogenesis of acne. In addition to the pathogenic   factors 
from the classical model, altered sebum lipid quality, 
regulation of steroidogenesis in the skin, interaction with 
  neuropeptidases, androgen activity, nutrition, and the 
  presence of any pro- and anti-inflammatory agents have also 
been implicated in acne development.10
The sebaceous gland plays a more prominent role in 
acne development. Sebaceous glands express neuropeptide 
(NP) receptors such as corticotrophin-releasing hormone, 
Β-endorphin, melanocortins, NP Y, vasoactive intestinal 
polypeptide, and calcitonin gene-related peptide. These 
receptors regulate several processes in human sebaceous 
cells, including the regulation of inflammatory cytokine pro-
duction, lipogenesis, and androgen metabolism.11,12 Further 
studies have shown that the keratinocytes and sebocytes of 
Figure 1 Sebaceous gland of normal skin.
Source: Graham Library of Digital Images, wake Forest University Department of 
Dermatology. © 2009 wake Forest University Dermatology.
Figure 2 Sebaceous gland of a young adult.
Source: Graham Library of Digital Images, wake Forest University Department of 
Dermatology. © 2009 wake Forest University Dermatology.
Figure 3 Acne vulgaris, comedone. (Cx7).
Source: Graham Library of Digital Images, wake Forest University Department of 
Dermatology. © 2009 wake Forest University Dermatology.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
81
Retinoid plus antimicrobial combination treatments for acne
the PSU act as immune cells that recognize pathogens such 
as P . acnes via toll-like receptors, CD14, and CD1 molecules, 
and additionally identify abnormal lipids which result in 
inflammatory cytokine production.10,13 The follicles affected 
in acne have surrounding macrophages that express toll-like 
receptor 2 on their surface, which acts to trigger the produc-
tion of cytokines and chemokines. The lipids produced by the 
sebaceous gland are increased in acne and play a role in signal 
transduction and biological pathways and also have pro- and 
anti-inflammatory characteristics.10,14 The fatty acids in the 
lipids act as ligands of peroxisome proliferator-activated 
receptors, and when induced, cause lipogenic activity.15
Androgen activity plays a crucial role in the pathogenesis 
of acne by influencing the proliferation and differentiation of 
sebocytes and infra-infundibular keratinocytes.10 Androgens   
may contribute to acne formation by initiating its development, 
by localized overproduction in the skin, or from the high 
expression or response of androgen receptors.10 The 
sebaceous gland expresses all of the enzymatic precursors 
necessary for testosterone synthesis, with the addition 
of 5α-reduced substances from dairy products or from 
circulating dehydroepiandrosterone.16,17
Investigation of the involvement of P . acnes in acne 
development remains controversial because of its presence 
as normal flora of human skin, and its pathogenic potential 
is not fully understood. Specific P . acnes strains can cause 
opportunistic infections that worsen acne.18 Antimicrobial 
peptides are present in noninflamed skin, which suggests that 
normal skin flora like P . acnes can facilitate the development 
of antimicrobial peptides without any inflammation.10 This 
can be beneficial in order to induce antibacterial effects; 
however, this also creates an environment that can promote 
increased resistance to other P . acnes strains.
Options for acne therapy
Approaching the management of acne is complex and requires 
consideration of the four main factors of its pathogenesis: 
disease duration and severity, past response to treatment, 
and skin color.4,19 No single topical or oral treatment can 
adequately address each component of therapy, and therefore 
several medications are usually required.3,19
Topical monotherapies can address three of the four 
causes of acne. However, no topical medicine can suppress 
excess sebum production.3,19 Topicals include retinoids, 
antibacterials, and benzoyl peroxide (BPO). Retinoids 
include tretinoin, isotretinoin, adapalene, and tazarotene. 
They act as keratolytics that have previously been reserved 
for noninflammatory lesions. There was concern of its 
association with skin irritation and an initial flare, both 
troublesome adverse effects (AEs).3,20 However, increasing 
evidence has led to the concept that retinoids can be used for 
inflammatory acne as a first-line treatment, with lesser skin 
irritation due to the development of newer generation retinoids, 
and retinoids can also aid in healing acne lesions.21,22 Also, 
clinical studies do not support the idea that topical retinoids 
worsen or flare acne during treatment.23 Antibacterials 
reduce the number of P . acnes, and can also work as weak 
comedolytics and anti-inflammatory agents.3 Long-term use 
of topical antibacterials cause resistant forms of P . acnes, 
and therefore is not recommended for chronic maintenance 
of acne. BPO is a mainstay of therapy for inflammatory acne 
and acts as an antibacterial and comedolytic agent.3,19,24 BPO 
can prevent bacterial resistance, thus contributing to safer, 
more eco-responsible acne management.25,26
Systemic medications for the treatment of acne are 
typically reserved for moderate and severe inflammatory 
acne, and include isotretinoin, antibacterials, and hormonal 
agents.3 Isotretinoin is a systemic retinoid that is highly 
effective for acne but carries a large systemic AE profile. 
Systemic antibiotics reduce the number of P . acnes, but have 
the risk of promoting bacterial resistance. They also carry 
AEs including gastrointestinal disturbances, photosensitivity, 
and vaginal yeast infections.3,27 Oral contraceptives can 
additionally be used, as the estrogen decreases the effect of 
androgens on the production of sebum.25
Adherence to acne therapy
With the greater risk of systemic AEs with oral therapies, 
several topical treatments may be prescribed. Topical 
application of medications is tedious, especially if multiple 
formulations have to be applied. This complicated treatment 
regimen for children to follow along with the chronic nature 
of the disease leads to poor medication adherence.28,29 Patients 
explain that failing to properly use their medications is in 
part due to forgetfulness and frustration.28,30,31 To improve 
adherence, simplifying treatment plans by way of decreas-
ing dosing schedule and combining medicines into a single 
formulation are beneficial.
Use of combination formulations  
in the treatment of acne
Patients could theoretically be asked to combine multiple 
monotherapy medications and use them once per day to sim-
plify their acne treatment regimen; however, it is unknown 
whether the active ingredients would remain stable and 
effective at lower concentration levels.28 This method may Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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also add undue cost to the patient. Therefore, specially 
formulated combination therapies have been developed. 
The goal of combination therapy is to target multiple areas 
of acne pathogenesis that could not be accomplished with 
monotherapy of either active ingredient, thereby improving 
outcome.1 Various combination drugs have been studied, 
including tretinoin plus topical antibiotics, and BPO plus anti-
biotics. The purpose of this review is to explore the literature 
on the efficacy and tolerability of combination clindamycin 
phosphate and tretinoin and other combination medications 
in the treatments of acne vulgaris.
Methods
A PubMed search was performed to identify articles with the 
keywords “clindamycin” and “tretinoin”, and “combination”. 
Original articles on clinical trials were selected, and related 
citations were evaluated. Review articles and meta-analyses 
were selected for a comprehensive review. Similar searches 
for benzoyl peroxide and clindamycin or erythromycin were 
performed. A PubMed search was also performed to identify 
articles with the keywords “adapalene” and “benzoyl peroxide” 
and “combination”. This search resulted in 20 manuscripts, 
of which 17 were relevant for review and included original 
articles on clinical trials, meta-analyses, and review articles. 
A Google search was used to identify updates on new formula-
tions for combination therapies. Reference lists from selected 
articles were used as a secondary method for obtaining articles 
and to evaluate the basis of the reviewed articles.
Results
Combination clindamycin phosphate  
and tretinoin
The combination product of clindamycin phosphate and 
tretinoin has been developed to target multiple areas of 
acne pathogenesis. Tretinoin acts as a comedolytic and 
anti-inflammatory, while clindamycin primarily acts as an 
antibacterial and decreases P . acnes counts.3 Together, the 
medications reduce comedogenesis and inflammation, and 
aid in the healing of acne lesions.21
There are currently two combination clindamycin and 
tretinoin products available. The first combination clindamy-
cin phosphate 1.2% and tretinoin 0.025% gel (CTG) was 
approved by the US Food and Drug Administration (FDA) 
for the treatment of acne vulgaris in patients 12 years and 
older in November 2006 (Ziana® Gel, Medicis Pharmaceutical 
  Corporation, Scottsdale, AZ). Another CTG formulation ini-
tially failed FDA approval in June 2005 because of concerns of 
dermal carcinogenicity in a single mouse model (Velac® Gel, 
Connetics Corporation, Palo Alto, CA). However, the CTG 
formulation was resubmitted and approved by the FDA in July 
2010 (Veltin® Gel, Stiefel Laboratories Inc, NC).32
CTG vs use of clindamycin phosphate 
plus tretinoin
Several studies have been performed that investigated the use 
of CTG combination therapy vs using two separate medications 
each day (Table 1). In 1983, Rietschel and Duncan investigated 
the use of combination therapy of clindamycin 1% and tretinoin 
0.025% gel vs monotherapy of clindamycin phosphate 1% plus 
tretinoin gel 0.025%.33 In this 8-week study, the combination 
regimen was not in a single formulation, but rather clindamycin 
phosphate applied in the morning and tretinoin at bedtime. All 
three programs resulted in lesion count reduction, but without 
significant differences between the study arms. Patient self 
evaluations found the most satisfactory improvement in 79% 
of the clindamycin monotherapy group, 68% in the tretinoin 
gel only group, and 65% in the combination therapy group. 
The combination therapy did not reduce patient tolerance of 
the medications, and the combination regimen had higher 
tolerability ratings than tretinoin gel. Also, clindamycin 
phosphate systemic absorption was undetectable at both 2 and 
8 weeks. This suggests the combination therapy has similar 
efficacy to monotherapy and does not result in more patient 
intolerance.
In 2010, Yentzer et al led a 12-week investigator-blinded, 
prospective, single-center, randomized, controlled trial that 
studied the efficacy and adherence of CTG vs dual use 
of separate clindamycin phosphate 1% gel and tretinoin 
0.025% in the treatment of mild-to-moderate acne.28 CTG 
was applied once daily in one group, while clindamycin 
phosphate was applied once in the morning and tretinoin was 
applied once at night in the other. Study participants were 
evaluated at weeks 4, 8, and 12 via an investigator global 
assessment.   Adherence was electronically monitored with 
Medication Event   Monitoring System® (MEMS) caps to 
record information on when the medication was opened, and 
patients were unaware of the use of the MEMS caps. Only the 
CTG group had improvement at week 4 of the study when 
combining the results of noninflammatory and total lesion 
counts (P # 0.05). Also, both groups improved in all areas 
of assessment by the end of the study, except for noninflam-
matory lesion reduction in the group using two separate 
medications (P , 0.05). Although not significant, the CTG 
group had a 51% mean reduction in total lesions vs 32% in the 
group using separate medications. A difference in adherence 
in the groups was found only at week 12 (P = 0.02). With Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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compliance to treatment defined as 80% or more adherence, 
67% of the CTG group and 8% of the group taking the 
separate medications were compliant. The CTG patients 
had no detected change in adherence over time (P = 0.24), 
while there was a significant drop in the separate agent group 
(P = 0.003). Although CTG use resulted in greater lesion 
reduction and better adherence, the correlation between the 
two was not statistically significant, which may have been 
due to the small study size. This investigation found that the 
use of a once-daily combination medication can encourage 
better adherence and clinical efficacy.
CTG vs tretinoin monotherapy
In 2006, Leyden et al compared CTG to monotherapy 
of its components and vs vehicle alone in two 12-week, 
randomized, double-blind, multicenter, active drug- and 
vehicle-controlled studies.34 A total of 634 patients were in 
the CTG arm of the study, with 635 in the tretinoin arm. There 
was a significantly greater reduction in inflammatory lesions 
in patients using CTG therapy (53.4%) vs the tretinoin only 
group (43.3%). The combination therapy group also reduced 
noninflammatory lesion counts (45.2%) vs tretinoin mono-
therapy (37.9%). The CTG group showed a significantly 
greater reduction in total lesion counts (48.7%) than tretinoin 
monotherapy (40.3%). At the end of the study, 37% of CTG 
subjects compared with 25% of tretinoin gel monotherapy 
subjects were clear or almost clear on Investigator’s Static 
Global Assessment (ISGA). Regarding tolerability, CTG 
and tretinoin monotherapy subjects had similar rates of AEs 
(19% vs 17%, respectively). This supported the efficacy 
of CTG over monotherapy in reducing inflammatory and 
noninflammatory acne lesions.
Table 1 Summary of investigations comparing CTG combination therapy to monotherapy of clindamycin, tretinoin, or vehicle
Study Drug Study design Study  
length
Study  
size (n)
Major results Safety/AE Other comments
Rietschel  
and 
Duncan33
Clindamycin 1%  
plus tretinoin  
0.025% vs  
monotherapy  
of clindamycin  
or tretinoin
Double-blind, 
randomized
8 weeks 64 Similar efficacy  
amongst tretinoin  
plus clindamycin,  
tretinoin alone, and  
clindamycin alone;  
all arms of the study  
were well-tolerated
Dryness and peeling 
worse with tretinoin 
alone; burning 
and erythema not 
significantly different 
between combination  
of drugs and  
tretinoin;  
clindamycin alone  
had least Aes
Absorption  
of cindamycin  
phosphate was  
not detected at  
2 and 8 weeks;  
combination therapy 
had fewer subjective 
complaints
Leyden  
et al34
CTG vs  
monotherapy  
of clindamycin  
or tretinoin  
or vehicle
Two randomized, 
double-blind,  
multicenter,  
active drug- and  
vehicle- 
controlled
12 weeks 2219 CTG group showed  
superior efficacy in  
treating inflammatory  
and noninflammatory  
lesions compared with 
monotherapy or  
vehicle alone
well-tolerated  
overall; 87.6% of 
participants  
reporting no Aes
Study conclusions 
may not represent 
predominantly 
inflammatory or 
nodulocystic acne; 
most subjects had 
noninflammatory 
acne
Yentzer  
et al28
CTG vs  
application of  
two separate  
generic  
subcomponents
Single-blind,  
prospective,  
single center,  
randomized,  
controlled trial
12 weeks 21 CTG group had  
significant reduction  
in total lesions over  
length of study;  
both groups improved  
mild to moderate acne
Treatment was well-
tolerated in both 
groups
Adherence of 
CTG product 
exceeded that of 
using two separate 
medications
Richter  
et al35
CTG vs  
0.025%  
tretinoin gel
Randomized,  
double-blind,  
multicenter
12 weeks 152 CTG was superior  
to tretinoin in papular  
and inflammatory acne  
lesions and in overall  
acne severity
Less burning  
reported with CTG
CTG onset of action 
was faster than 
tretinoin
Zouboulis  
et al36
CTG vs  
clindamycin  
lotion
Multicenter,  
single-blind,  
randomized,  
comparative
12 weeks 206 CTG was more  
effective at reducing  
acne lesions than  
clindamycin  
monotherapy
More erythema and 
desquamation  
reported with CTG
CTG had faster 
onset of action 
than clindamycin 
monotherapy
Abbreviations: Ae, adverse effect; CTG, clinamycin 1.0%–1.2%-tretinoin 0.025% combination gel.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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In 1998, Richter et al conducted a 12-week, double-blind, 
randomized, multicenter study of 161 patients to compare 
the efficacy and safety of CTG in moderate to severe acne 
vs monotherapy of tretinoin, with some similar results.35 
The efficacy of each treatment regimen was evaluated at 4, 8, 
and 12 weeks by calculating an overall acne severity grade and 
assessing its improvement over time. AEs were graded and 
recorded by investigator assessments at weeks 2, 4, 8, and 12. 
There was no difference in the reduction of open comedones in 
the CTG group vs the tretinoin group at the end of the study, 
at 58% and 53%, respectively (P = 0.3), or the reduction of 
closed comedones, at 65% and 52%, respectively (P = 0.06). 
The reduction of total lesions with CTG treatment vs tretinoin 
treatment was 61% and 55%, respectively (P = 0.15). CTG 
was more effective than tretinoin at reducing papules at each 
of the 3 weeks of assessment (P = 0.04, 0.01, and 0.0004 at 
weeks 4, 8, and 12, respectively), but there was no   difference 
in pustule or nodule reduction. CTG was more effective in 
reducing the quantity of inflammatory acne lesions   during 
treatment with a 73% reduction vs 54% with tretinoin 
(P = 0.006 at 12 weeks). This decrease occurred about 60% 
faster as well. Overall acne severity grade improved 64% 
over the length of the study for CTG and 54% for tretinoin 
 ( P = 0.01). Authors concluded that CTG efficacy was superior 
to tretinoin monotherapy in papular and inflammatory lesions, 
as well as in overall acne severity. CTG also reported less 
burning, but this may have been due to an emollient added 
in the CTG vehicle formulation.
CTG vs clindamycin monotherapy
Zouboulis et al performed a 12-week, Phase III, multicenter, 
single-blind, randomized, comparative study on 206 subjects 
to investigate the efficacy and safety of CTG vs clindamycin 
1% lotion for moderate-to-severe acne.36 CTG was applied 
once daily, and the clindamycin lotion was applied twice 
daily. Efficacy, AEs, medications, the overall acne severity 
grade, and compliance were all assessed at baseline and at 
weeks 2, 4, 8, and 12 of the study. Compliance was evaluated 
by recording missed applications at each follow-up visit.
The absolute lesion reduction was 69.2% for the CTG 
group vs 60.9% for the clindamycin group (P = 0.05). 
Reduction of noninflammatory lesions at the end of the 
study was 66.8% for CTG vs 59.9% for the clindamycin 
group. The absolute reduction of inflamed lesions at week 
12 was greater for CTG than clindamycin (P = 0.018), and 
was true for all inflammatory lesions (papules, pustules, and 
nodules). In the per protocol group, the reduction of pustules 
over the length of the study was significant in the CTG group 
compared with clindamycin monotherapy (P = 0.031), and 
the reduction in nodules neared significance (P = 0.062). 
Absolute reduction of acne severity score was observed 
at week 12 for both the overall score (P = 0.03) and mean 
  percentage (P , 0.01). Subjective assessment of overall acne 
severity using the Cook scale found a greater reduction in the 
CTG group over the 12-week study (P = 0.007). Regarding 
rapidity of effects, the CTG group had more individuals with 
a 50% reduction in total lesions by day 60 (77%) than the 
clindamycin lotion group (56%) (P = 0.003). Open comedone 
reduction contributed largely to the more rapid effect of onset 
of CTG (P = 0.0006). Both groups showed moderate or good 
improvement in the overall analysis and were generally well-
tolerated. This demonstrates that once daily use of CTG is 
at least as effective as clindamycin 1% lotion applied twice 
daily, while also having a quicker onset of action.
Leyden et al in 2006 also compared CTG with clindamycin, 
including 634 participants in the CTG group vs 635 in the 
clindamycin monotherapy group.34 There was a 53.4% 
reduction of inflammatory lesions using CTG vs 47.5% of 
clindamycin only subjects, as well as a 45.2% vs 31.6% 
mean reduction of noninflammatory lesions in the CTG 
and clindamycin groups, respectively. Total lesion count 
reductions were 48.7% in the CTG group vs 38.3% in the 
clindamycin group. ISGA showed 37% of CTG participants 
were clear or almost clear after 12 weeks of treatment 
compared with 27% of clindamycin gel only subjects. Each 
of these parameters demonstrated greater efficacy of CTG 
therapy vs clindamycin monotherapy. However, fewer 
subjects in the clindamycin arm reported AEs (5%) compared 
with the CTG group (19%).
Associations with acne flares
The original formulations of tretinoin had a 0.05% concentra-
tion in a hydroalcohol vehicle, and nearly 20% of patients 
reported AEs, including acne flares, within a few weeks of 
initiating treatment.37 Thus, the use of tretinoin was hesitat-
ingly used for acne, particularly with the inflammatory type. 
Schlessinger et al investigated an evaluation of flaring of 
inflammatory lesions after 2 weeks of therapy with either 
CTG, clindamycin phosphate 1.2%, tretinoin 0.025% gel, 
or vehicle monotherapy.38 Flaring was defined as a 20% or 
more increase in inflammatory lesion count. In patients with 
moderate-to-severe acne, the subjects using only vehicle 
experienced the greatest acne flare (12.1% in moderate 
cases, 12.7% in severe). In mild acne, tretinoin monotherapy 
resulted in the greatest percentage of flares (9.9%) followed 
by clindamycin (7.7%). For mild and moderate acne, CTG Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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showed the lowest percentage of acne flares (4.2%, 5.6%, 
and 7.5% for mild, moderate, and severe, respectively). 
The authors concluded that except for subjects with mild 
inflammatory acne, there was no evidence of acne flaring 
caused by tretinoin use. This conclusion is consistent with 
the known anti-inflammatory effects of clindamycin, and 
that new vehicle formulations are utilized with tretinoin gel 
and CTG.37,38
Aes
AEs reported from Phase III studies by the manufacturers of 
CTGs are shown in Table 2. At 12 weeks, at least one AE 
was reported in 27% of CTG patients, 24% for clindamycin, 
27% for tretinoin gel, and 22% for vehicle gel.39,40 Nasophar-
yngitis ranged among all groups from 1% to 5%, followed 
by pharyngolaryngeal pain (1%–2%), dry skin (0%–1%), 
cough (1%–2%), and sinusitis (1%–2%). These AEs occurred 
in about equal percentages amongst all groups, were most 
likely due to general medical conditions or local application 
site reactions, and occurred as expected.38,41
Local skin reactions were also summarized for all 
Phase III studies on CTG therapy (Table 3).39,40 Erythema, 
scaling, itching, burning, and stinging were all reported. 
  Erythema was the most common local skin reaction over-
all, and decreased slightly in frequency from baseline to 
the end of treatment (35% and 26%, respectively). Scaling 
was reported in 13% at baseline and 17% at the end of 
treatment. Itching was found in 10% of subjects at baseline 
and decreased to 4% by the end of treatment. Burning and 
stinging were both reported to be less than 5% at both base-
line and at the end of treatment. The incidence of local skin 
reactions was either minimally increased or decreased by 
the end of treatment.38
The trial by Zouboulis et al reported erythema and skin 
desquamation occur more often in subjects using CTG 
than clindamycin monotherapy.36 When AEs occurred with 
CTG use, application site dryness, desquamation, burning, 
erythema, and pruritus were more common in subjects 
using CTG than in clindamycin, tretinoin, or vehicle 
monotherapy.34 The AE incidence using CTG paralleled 
that in tretinoin for dryness (9% vs 8%), desquamation 
(8% vs 7%), burning (6% vs 5%), and pruritus (4% vs 3%), 
and were more common than in the clindamycin or vehicle 
monotherapy groups. Although AEs occurred, they were 
expected, and notably AEs are more commonly not reported. 
In one report of 2219 subjects, 87.6% reported no AEs over 
the course of the 12-week study.34 Kircik et al investigated 
AEs and safety for CTG with a 6- or 12-month duration, 
multicenter, open-label study. In long-term treatment, 92%, 
91%, and 94% of all participants (N = 655) reported no 
itching, burning, or stinging, respectively.42 Most studies 
conclude CTG combination therapy as being well-tolerated 
overall.28,33,34,36,41–43
Safety considerations
There are two major safety issues to consider with CTGs. 
Topical clindamycin has been associated with pseudomem-
branous colitis due to overgrowth of Clostridium difficile, 
and systemic circulation of retinoids is known for being a 
teratogenic. With the suspicion of increased permeability of 
the skin with a combination formulation such as CTG due 
to the enhancing effects of tretinoin, van Hoogdalem et al 
investigated the transdermal uptake of both tretinoin and 
clindamycin from CTG.43 After 5 days of daily application to 
the face, percutaneous absorption of clindamycin phosphate 
in plasma samples were immeasurable (,5 ng/mL), while 
plasma levels of clindamycin HCl topical were as high as 
13 ng/mL (n = 12). Urinary excretion of clindamycin from 
both the combination medicine and reference clindamycin 
lotion was comparable in all but one subject. This subject had 
increased excretion, but the patient had irritated, peeling skin 
contributing to the increased uptake of drug. In a separate 
study of acne patients in the same manuscript, CTG use did 
not cause a measurable transdermal uptake of tretinoin after 
Table 2 Aes occurring in at least 1% of subjects at the end of 12-week study39,40
CTG  
N = 1853  
N (%)
Clindamycin phosphate  
1.2% N = 1428  
N (%)
Tretinoin 0.025% gel  
N = 846  
N (%)
Vehicle gel   
N = 423  
N (%)
Patients with at least 1 Ae 497 (27) 342 (24) 225 (27) 91 (22)
Nasopharyngitis 65 (4) 64 (5) 16 (2) 5 (1)
Pharyngolaryngeal pain 29 (2) 18 (1) 5 (1) 7 (2)
Dry skin 23 (1) 7 (1) 3 (,1) 0 (0)
Cough 19 (1) 21 (2) 9 (1) 2 (1)
Sinusitis 19 (1) 19 (1) 15 (2) 4 (1)
Abbreviations: Ae, adverse effect; CTG, clinamycin 1.0%–1.2%-tretinoin 0.025% combination gel.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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12 weeks, clindamycin levels were not quantifiable in 87% 
of patients, and the highest clindamycin level was 11 mL–1 
(n = 40). These studies support the notion that clindamycin 
uptake in the presence of tretinoin in combination therapy 
is not increased, and the risk of pseudomembranous colitis 
with combination clindamycin phosphate and tretinoin is 
low. However, combination therapy should be discontinued 
if significant diarrhea occurs.39,40
The safety of CTG use during pregnancy is still unknown 
and is classified as a category C drug.39,40 All studies have 
excluded both pregnant and lactating females. It is recom-
mended to avoid use of CTG in this patient subpopulation 
unless its benefit of use is determined to outweigh the 
potential risks.
Other combination acne combination 
therapies
Various other combination products on the marketplace also 
incorporate a topical antibiotic, such as topical clindamycin 
or erythromycin. Some utilize BPO, which acts via a different 
mechanism as an antibacterial agent and comedolytic agent, 
as a replacement for the tretinoin used in CTG.
Combination BPO and clindamycin  
(BPO/clin)
Several studies investigated the benefit of a combined formu-
lation of BPO/clin vs monotherapy of either drug (Table 4). 
Lookingbill et al performed an 11-week, double-blind, ran-
domized, parallel, controlled study of 334 subjects comparing 
BPO/clin (5%/1%) to monotherapy of either drug of similar 
concentrations or vehicle.44 The BPO/clin combination had 
greater efficacy than monotherapy of either drug or vehicle, 
and the combination drug was well-tolerated.
Leyden et al also studied the efficacy of BPO/clin 
(5%/1%) vs monotherapy of either BPO (5%), clindamycin 
(1%), or vehicle.45 Again, BPO/clin was more effective than 
either of its active drugs alone as an alternative treatment 
of moderate or moderately severe acne. The combination 
formulation was well-tolerated, with dry skin the most 
frequently reported AE in all groups, and its AE profile was 
similar to that of BPO monotherapy.
In a separate investigation, Leyden et al compared 
combination BPO/clin (5%/1%) vs BPO (5%) alone and 
BPO/erythromycin (5%/3%) in 492 subjects.46 BPO/clin 
was more efficacious than BPO monotherapy for reducing 
inflammatory lesions, and there was no difference in efficacy 
between the two combination therapies. AEs were similar 
amongst all three groups, with skin dryness most commonly 
reported, but overall the medications in all groups were 
well-tolerated. Thus, BPO/clin combination therapy is an 
efficacious, tolerable, and safe alternative therapy for the 
treatment of moderate-to-moderately severe acne vulgaris.
A total of 287 patients with moderate to moderately 
severe acne was performed by Tschen et al, which also 
compared BPO/clin to monotherapy of BPO, topical 
clindamycin, or vehicle.47 BPO/clin reduced inflammatory 
lesions more than either drug alone. Also, the combination 
medication reduced comedones more than clindamycin 
or vehicle, but not compared with BPO monotherapy. 
Tolerability was good for all medicines used. Dry skin was 
the most frequent AE and more common in the BPO/clin and 
BPO groups. This investigation concluded that BPO/clin was 
more effective than monotherapy of either drug, especially 
for inflammatory acne.
Thiboutot et al compared BPO/clin (2.5%/1.2%) to 
monotherapy of BPO, clindamycin phosphate, or vehicle in 
the largest subject study for acne vulgaris (n = 2813).48 The 
12-week multicenter, randomized, double-blind, active- and 
parallel-group, comparative study evaluated BPO/clin for the 
treatment of moderate-to-severe acne. BPO/clin was more 
effective for treating both noninflammatory and inflammatory 
lesions than monotherapy of either active drug or vehicle. 
The combination drug was well-tolerated, and any reported 
AEs were mild-to-moderate in nature. Thus, a larger study 
shows BPO/clin as safe, effective, and well-tolerated for the 
treatment of acne vulgaris.
Cunliffe et al compared BPO/clin (5%/1%) to clin-
damycin 1% gel for clinical efficacy and reductions in 
P . acnes and clindamycin-resistant P . acnes counts.49 After 
16 weeks of treatment in 70 subjects, BPO/clin therapy 
reduced the number of P . acnes and clindamycin-resistant 
P . acnes counts significantly more than topical clindamycin 
monotherapy. Use of clindamycin alone actually increased 
bacteria counts . 1600% after 16 weeks of treatment. Both 
preparations were well-tolerated by the study participants. 
This demonstrated a correlation exists between acne lesion 
Table 3 Local skin reactions reported with CTG39,40
Local reaction Baseline  
N = 1835  
N (%)
End of treatment   
N = 1614  
N (%)
erythema 636 (35) 416 (26)
Scaling 237 (13) 280 (17)
Itching 189 (10) 70 (4)
Burning 38 (2) 56 (4)
Stinging 33 (2) 27 (2)
Abbreviation: CTG, clinamycin 1.0%–1.2%-tretinoin 0.025% combination gel.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Table 4 Summary of comparative investigations of BPO/clin or BPO/erythro combination therapies vs monotherapy of either drug’s 
constituents and vehicle
Study Drug Study design Study 
length
Study  
size (n)
Major results Safety/AE Other comments
Lookingbill  
et al44
BPO/clin (5%/1%)  
vs monotherapy  
of BPO (5%) or  
clin (1%) or vehicle
Two double-blind, 
randomized,  
parallel,  
controlled
11 weeks 334 BPO/clin showed  
greater efficacy  
than monotherapy  
of BPO, clin,  
or vehicle
excellent overall  
tolerance reported  
in 95% of patients;  
no difference in Aes  
in active drug arms
Concluded that 
combination BPO/
clin is superior to 
either drug alone
Leyden  
et al45
BPO/clin (5%/1%)  
vs monotherapy  
of BPO (5%) or  
clin (1%) or vehicle
Multicenter, 
randomized,  
double-blind
10 weeks 480 BPO/clin more  
effective than  
monotherapy  
of BPO, clin,  
or vehicle
Similar Aes in all  
arms of study; most 
common Ae was  
skin dryness
Concluded 
combination BPO/
clin as an alternative 
treatment for 
moderate to 
moderately 
severe acne
Leyden  
et al46
BPO/clin (5%/1%)  
vs BPO (5%) or  
BPO/erythro  
(5%/3%)
Randomized, 
multicenter,  
single-blind
10 weeks 492 BPO/clin showed  
greater reduction  
than BPO in 
inflammatory lesions 
and was not more  
efficacious than  
BPO/erythro
Aes similar in all  
arms; dry skin most 
frequently reported  
in all arms
Concluded BPO/clin 
combination more 
effective than BPO 
alone and at least  
as effective as  
BPO/erythro
Tschen  
et al47
BPO/clin (5%/1%)  
vs BPO (5%) vs  
clin (1%) vs vehicle
Randomized, 
multicenter,  
double-blind,  
parallel-group
10 weeks 278 BPO/clin reduced 
inflammatory  
lesions more than 
either drug alone; 
BPO/clin reduced 
comedones more 
than clin or vehicle
Dry skin most  
frequent Ae overall  
and more common  
in BPO/clin and BPO
Concluded BPO/
clin more effective 
than monotherapy 
of either drug, 
especially for 
inflammatory acne
Thiboutot  
et al48
BPO/clin  
(2.5%/1.2%)  
vs BPO (2.5%) vs  
clin (1.2%) vs  
vehicle
Multicenter, 
randomized,  
double-blind,  
active- and  
vehicle-controlled,  
parallel-group,  
comparative
12 weeks 2813 BPO/clin was  
more effective  
at treating both  
noninflammatory  
and inflammatory  
lesions than either  
drug alone or  
vehicle
BPO/clin preparation  
was well-tolerated,  
and the Aes reported 
were reported as  
mild to moderate
BPO/clin is a safe, 
effective, and well-
tolerated agent for 
the treatment of 
moderate to  
severe acne
Cunliffe  
et al49
BPO/clin (5%/1%)  
vs clin 1% gel
Double-blind,  
randomized,  
parallel-group
16 weeks 70 BPO/clin reduced  
number of  
Propionibacterium  
acnes and  
clin-resistant  
P. acnes; clin  
monotherapy  
increased bacteria  
count; BPO/clin  
showed better  
efficacy than clin
Both preparations  
were well-tolerated
Decreasing P. acnes 
and clin-resistant 
P. acnes counts 
correlated with the 
reduction in total 
acne lesions
Chalker  
et al51
BPO/erythro  
(5%/3%) vs BPO  
(5%) vs erythro  
(3%) vs vehicle
Double-blind,  
controlled
10 weeks 165 BPO-containing 
products reduced 
comedones more 
effectively than 
erythro alone; 
reduced pustules, 
papules, and 
inflammatory  
lesions
No Aes reported BPO/erythro 
more effective 
than either drug 
alone, especially 
for inflammatory 
lesions
Abbreviations: Ae, adverse effect; BPO, benzoyl peroxide; BPO/clin, benzoyl peroxide/clindamycin phosphate combination medication; BPO/erythro, benzoyl peroxide/
erythromycin combination medication; clin, clindamycin phosphate; erythro, erythromycin.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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counts and the number of P . acnes and clindamycin-resistant 
P . acnes.
All studies reviewed demonstrated that combination 
therapy was more effective than monotherapy of either BPO 
or clindamycin in the treatment of acne vulgaris, particularly 
for the treatment of inflammatory lesions. Although the 
superiority in efficacy of BPO/clin combination therapy over 
monotherapy of either drug alone has been demonstrated, the 
value of this in clinical practice needs to be considered by 
the practitioner as to whether this data in combination with 
other factors like cost, risks including bacterial resistance, 
and availability.50
Combination BPO and erythromycin 
(BPO/erythro)
Chalker et al completed a 10-week study on 165 participants 
that compared the efficacy of BPO/erythro (5%/3%) com-
bination therapy to monotherapy of each drug and vehicle 
(Table 4).51 The BPO-containing products, BPO/erythro and 
BPO monotherapy, reduced comedones more than erythro-
mycin alone, but not significantly. Also, combination therapy 
reduced pustules and papules, but no more than either drug 
alone. BPO/erythro significantly reduced the number of 
inflammatory lesions better than either drug alone or the 
vehicle. There were no reported AEs. Thus, particularly for 
inflammatory lesions, BPO/erythro was more effective than 
either drug alone.
As previously discussed, Leyden et al compared BPO/clin 
(5%/1%) vs BPO (5%) or BPO/erythro (5%/3%) in a 10-week 
study of 492 patients, showing no differences between the 
two combination therapies, however BPO/erythro was more 
efficacious than BPO alone.46
Combination adapalene and BPO 
(adapalene-BPO)
A new, potent combination regimen incorporates adapalene, 
a retinoid, plus BPO, where BPO acts as a bactericidal agent 
and decreases inflammation, and a retinoid acts on both 
comedonal and inflammatory lesions without the need for 
an antibiotic.19,21,22 Several trials have assessed the efficacy 
and tolerability of the combination adapalene-BPO gel vs 
monotherapies of either drug and its vehicle (Table 5). All 
of the studies reported superior efficacy of the combination 
product vs monotherapies of either drug.52–55 Few clinical 
trials only investigated the tolerability of the combination 
product vs monotherapies and found good tolerability over-
all when compared with monotherapy of either drug and a 
similar AE profile to adapalene monotherapy.56–58 Troielli et al 
investigated the use of adapalene-BPO in the community 
setting and found the combination therapy demonstrates good 
efficacy and tolerability in general practice.56
Zouboulis et al directly compared the combination 
therapies adapalene-BPO and BPO/clin.59 They found that 
the two combination therapies have a similar efficacy profile 
in reducing both inflammatory and noninflammatory lesions; 
however, they concluded that the BPO/clin product results 
in better treatment success with a better tolerability profile 
and safety profile than adapalene-BPO.
A subgroup analysis by Eichenfield et al investigated 
the efficacy and safety of an adapalene/BPO (0.1%/2.5%) 
combination gel in acne, showing the combination therapy 
was more effective than monotherapies or vehicle alone 
and had an onset of action of 1 week.60 The early onset 
of action and combination dosing can aid in increased 
adherence and therapeutic outcome because of its ease of 
use in a single formulation and its high treatment efficacy. 
This medication also avoids the potential for bacterial 
resistance and includes two mainstays in the treatment of 
acne vulgaris.
Discussion
The use of combination therapy is established as a superior 
treatment plan to monotherapy in acne vulgaris because 
it targets multiple factors of its pathogenesis.3 Combining 
medications also results in increased adherence and better 
therapeutic outcomes by reducing the complexity of acne 
management.28 The combination of clindamycin phosphate 
and tretinoin treatment works to decrease inflammation, 
reduces P . acnes counts, acts as a comedolytic, and reduces 
comedogenesis. CTG is indicated for mild-to-moderate 
acne; however, studies have investigated the use of CTG 
for moderate-to-severe acne either alone or in conjunction 
with other therapies.35,36 The ability for CTG to decrease 
inflammatory lesions can aid in more severe forms of acne 
and can be considered as an alternative agent in treatment.
Other antibiotic-containing combination therapies 
include BPO and either clindamycin or erythromycin. 
These combination therapies were also more efficacious in 
treating mild-to-moderate acne and are well-tolerated. When 
combination BPO and either clindamycin or erythromycin are 
compared with one another for efficacy, there is no significant 
difference in outcome.46
One limitation of the use of combination medica-
tions that include antibiotics is the potential for bacte-
rial resistance while using topical antibiotics, and more 
eco-responsible alternatives should be considered when Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Table 5 Summary of comparative investigations of adapalene-BPO combination therapies vs monotherapy of each and vehicle
Author Drug Study design Study  
length
Study  
size (n)
Major results Safety/AE Other comments
Poulin  
et al52
Adapalene-BPO  
vs vehicle
Multicenter,  
double-blind,  
randomized,  
controlled
12 weeks 243 Significantly higher 
lesion maintenance 
success rate for 
inflammatory and 
noninflammatory 
lesions with  
adapalene- 
BPO vs vehicle
Adapalene-BPO  
was safe and  
well-tolerated
Adapalene-BPO 
prevents the relapse 
in severe acne and 
continues to reduce 
lesion counts over  
6 months
Troielli  
et al56
Adapalene-BPO Open-label,  
community-based,  
multicenter,  
interventional
12 weeks 105 Adapalene-BPO use 
significantly  
decreased 
inflammatory and 
noninflammatory 
lesions
Good local  
tolerability
Adapalene-BPO has 
good efficacy and 
tolerability in routine 
practice
Gold  
et al53
Adapalene-BPO vs 
monotherapy of  
either drug alone  
and gel vehicle
Multicenter, 
randomized,  
double-blind,  
parallel-group,  
active- and  
vehicle-controlled
12 weeks 1429 Adapalene-BPO 
showed higher  
success rate and  
reduction of acne  
lesions than other  
groups
comparable safety  
of adapalene-BPO  
to monotherapies  
and gel vehicle
Large clinical trial 
demonstrates fixed-
dose combination 
therapy to be 
superior in efficacy 
with an early onset  
of efficacy
Gollnick  
et al54
Adapalene-BPO vs 
monotherapy of  
either drug alone  
and gel vehicle
Randomized,  
double-blind,  
controlled
12 weeks 1670 Adapalene-BPO 
showed significantly 
greater efficacy  
than monotherapies
well-tolerated,  
with comparable  
tolerability to a 
dapalene  
monotherapy
Adapalene-BPO use 
results in significantly 
greater and 
synergistic results  
in the treatment 
of acne vulgaris 
compared with 
monotherapies
Loesche  
et al58
Adapalene-BPO vs 
monotherapy of  
either drug alone  
and gel vehicle
Single center,  
controlled,  
randomized,  
investigator-blinded  
intra-individual
3 weeks 24 Study analyzed tolerability only;  
no significant difference in irritation  
indices for adapalene-BPO vs  
monotherapies
Adapalene-BPO is 
as well-tolerated as 
either monotherapy 
in relation to 
irritancy
Andres  
et al57
Adapalene-BPO vs  
BPO 2.5%;  
adapalene-BPO vs  
BPO 5%; adapalene  
0.1%-BPO 5%  
combination vs  
BPO 5%; and  
adapalene  
0.1%-BPO  
5% combination  
vs BPO 10%
Randomized,  
controlled,  
investigator- 
blinded,  
single-center,  
bilateral (split-face), 
dose-assessment
3 weeks 60 Study analyzed tolerability only; better 
tolerability profile of adapalene 0.1%-BPO 
2.5% than adapalene 0.1%-BPO 5%; similar 
to either BPO 2.5% or 5% monotherapy; 
adapalene 0.1%-BPO 5% caused more 
irritation than BPO 5% or  
10% monotherapy
Adapalene 0.1%-BPO 
2.5% combination 
product had best 
tolerability profile 
compared with BPO 
monotherapy
Thiboutot 
et al55
Adapalene-BPO vs 
monotherapy of  
either drug alone  
and gel vehicle
Randomized,  
double-blind,  
controlled
12 weeks 517 Adapalene-BPO 
significantly more 
effective than 
monotherapies with 
significant reduction  
in lesion counts at  
1 week
Similar adverse  
event frequency  
and tolerability  
profile for  
combination gel  
vs adapalene  
monotherapy
Adapalene-BPO use 
results in significantly 
greater efficacy for 
treatment of acne 
vulgaris compared  
to monotherapies 
and a similar 
tolerability profile 
to adapalene 
monotherapy
Abbreviations: adapalene-BPO, adapalene 0.1%/benzoyl peroxide 2.5% combination gel; BPO, benzoyl peroxide.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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appropriate.25 BPO is a mainstay of mild-to-moderate acne 
therapy and an alternative to antibiotic use for manage-
ment. Incorporating BPO into one’s treatment regimen 
can reduce antibiotic resistance when used with a topical 
antibiotic and can be used long-term.25,26 Combination 
products that combine BPO are thus a reasonable alterna-
tive. Eady et al investigated the use of combination BPO 
and erythromycin treatment and its effects on P . acnes 
and erythromycin-resistant P . acnes and found combin-
ing medications results in greater reductions of bacte-
rial counts and also better clinical outcomes in patients 
already colonized with resistant strains of P . acnes.61 
Although combining BPO with an antibiotic can reduce 
  bacterial counts with good clinical outcomes, taking 
measures to reduce the initial problem of drug-resistant 
bacteria by the physician is prudent.
The combination product of a retinoid plus BPO, such 
as adapalene-BPO, should be strongly considered for acne 
vulgaris. Feldman et al analyzed several clinical trials on 
adapalene-BPO and found that its benefit increases with 
higher lesion counts at the beginning of the study.62 This 
data suggests that adapalene-BPO therapy may be suitable 
for more severe forms of acne; however, the combination 
product was studied on inflammatory and noninflammatory 
lesions and is also found to be efficacious in milder forms 
of acne. The versatility of its efficacy suggests that its use 
should be considered in the spectrum of mild-to-severe acne. 
It also has the added benefit of a BPO, which is not associated 
with antibiotic resistance.
A combination retinoid with antimicrobial medication 
is effective for both inflammatory and noninflammatory 
acne. It has a faster onset of action than either drug alone 
and is considered to be well-tolerated and safe for most 
patients. A combination product leads to increased adher-
ence and greater clinical outcome. BPO and antibiotic 
combination formulations are also more efficacious than 
either treatment alone with a good tolerability profile. The 
concern for bacterial resistance arises when using topical 
antibiotics, thus a combination product containing other 
active medications like a retinoid plus BPO should be 
considered for therapy.
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